EMERYVILLE, Calif.–(BUSINESS WIRE)–NovaBay Pharmaceuticals Announces Restructuring to Focus on Avenova Commercialization and Reports Third Quarter Financial Results
Category: Business
RetroSense Therapeutics’ Clinical-Stage Development Program to Restore Vision Wins Multiple Awards
ANN ARBOR, Mich.–(BUSINESS WIRE)–Therapeutic Area Partnerships has selected RetroSense lead compound, RST-001, as a “Top Project to Watch: Most Licensable Products” and also won the “Deals of the Year” Research Award.
Aerpio Therapeutics Reports Positive Clinical Results from the Phase 2a Study of Lead Candidate, AKB-9778, in Diabetic Macular Edema (DME): The TIME-2 Trial
CINCINNATI–(BUSINESS WIRE)–Aerpio Therapeutics, Inc., a biopharmaceutical company focused on advancing first-in-class treatments for the eye, today announced that clinical data from the company’s phase 2a study of its lead candidate, AKB-9778, for the treatment of patients with DME, were reported in an oral presentation delivered by Peter Campochiaro, MD, from Johns Hopkins Wilmer Eye Institute, during the Retina Subspecialty Day at the ongoing American Academy of Ophthalmology (AAO) Annual M
Ophthotech Announces that Genentech, a Roche Wholly-Owned Subsidiary, Elects to Exercise Its Right to Opt-in to the Novartis Portion of the Ophthotech / Novartis Ex-US Agreement for Fovista® to Treat Wet Age-Related Macular Degeneration
NEW YORK–(BUSINESS WIRE)–Ophthotech announced that Genentech has elected to exercise its option to participate in the financial arrangements relating to Novartis’ rights under the Ophthotech/Novartis ex-US agreement.
New High Resolution Fundus Cameras VISUCAM 224 / 524 for More Confident Diagnosis
JENA, Germany & LAS VEGAS–(BUSINESS WIRE)–New high resolution Fundus Cameras VISUCAM 224 / 524 for more confident diagnosis; ZEISS introduces a new generation of high resolution Fundus cameras at the American Academy of Ophthalmology
ZEISS Presents Innovations That Support Ophthalmologists in Their Work
JENA, Germany & LAS VEGAS–(BUSINESS WIRE)–ZEISS presents innovations that support ophthalmologists in their work;
At the 2015 Annual Meeting of the American Academy of Ophthalmology (AAO) in Las Vegas, ZEISS announces innovations
Clarity Announces Commercial Availability of HOLOS IntraOpTM Technology
LAS VEGAS–(BUSINESS WIRE)–Clarity Medical Systems, Inc. (Clarity), a medical device company focused on the manufacture of integrated optical systems for the diagnosis and management of eye disorders, announces the commercial availability of its HOLOS…
Tobii AB: Tobii Receives Order for Eye-Tracking Platforms from MSI
STOCKHOLM–(BUSINESS WIRE)–Regulatory News: Tobii AB (Nasdaq Stockholm: TOBII) has received the first purchase order from Micro-Star International Co. Ltd (MSI) for its eye-tracking platform Tobii IS3. The platforms are to be used in premium gaming notebooks from MSI. Deliveries are planned to begin at the turn of 2015/2016. “This order is for integration of eye tracking in a high-end gaming notebook. This means that the initial volume is low, however it’s still an important milestone since it
Modernizing Medicine Showcases Built-in ICD-10 Coding and PQRS Reporting in EMA Ophthalmology EMR System at American Academy of Ophthalmology (AAO)
BOCA RATON, Fla.–(BUSINESS WIRE)–Modernizing Medicine will unveil the latest enhancements of EMA Ophthalmology at this year’s American Academy of Ophthalmology (AAO).
The Retina Group of Washington Selects Modernizing Medicine’s EMA Ophthalmology® EMR System to Streamline Physician Workflow and Improve Patient Care
BOCA RATON, Fla.–(BUSINESS WIRE)–Modernizing Medicine announced today that The Retina Group of Washington has selected EMA Ophthalmology to replace its legacy EMR solution.
NovaBay Pharmaceuticals Reschedules Third Quarter 2015 Conference Call to November 16
EMERYVILLE, Calif.–(BUSINESS WIRE)–NovaBay Pharmaceuticals will hold its third quarter 2015 investment community conference call on November 16 at 8:30 a.m. ET
Ocular Therapeutix™ Reports Third Quarter 2015 Financial Results
BEDFORD, Mass.–(BUSINESS WIRE)–Ocular Therapeutix™, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the development and commercialization of innovative therapies for diseases and conditions of the eye, today announced financial results for the third quarter ended September 30, 2015. “Our product development programs advanced meaningfully during the third quarter with an NDA submission to the Food and Drug Administration for our lead product candidate, DEXTENZA for a post-surgical o
Glaukos Corporation Announces Third Quarter 2015 Financial Results
LAGUNA HILLS, Calif.–(BUSINESS WIRE)–Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures designed to transform the treatment of glaucoma, …
FDA Accepts PMA Submission for ReVision Optics’ Raindrop Near Vision Inlay
LAKE FOREST, Calif.–(BUSINESS WIRE)–ReVision Optics, Inc. (RVO®), a leader in implantable presbyopia-correcting corneal inlay technology, announces that the U.S. Food and Drug Administration (FDA) has accepted and deemed fileable the company’s premarket approval (PMA) submission for the Raindrop® Near Vision Inlay. The Raindrop is a microscopic hydrogel inlay designed to correct presbyopia, thus reducing or eliminating the need for reading glasses. Acceptance and filing of the submission mean
Ocular Therapeutix™ Expands Its Board of Directors with the Election of Industry Leader W. James O’Shea
BEDFORD, Mass.–(BUSINESS WIRE)–Ocular Therapeutix™, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the development and commercialization of innovative therapies for diseases and conditions of the eye, announced today that W. James O’Shea, former President and Chief Operating Officer of Sepracor Inc., has been elected to Ocular’s Board of Directors. “We are very pleased to announce that Jim is joining our Board. With a more than 40-year tenure in the biopharma industry, Jim has ext
Research and Markets: Global Ophthalmology Devices – Industry Analysis 2015-2019 – Growing attention toward subtypes of eye diseases
DUBLIN–(BUSINESS WIRE)–Research and Markets (http://www.researchandmarkets.com/research/n7kfbw/global) has announced the addition of the “Global Ophthalmology Devices – Industry Analysis 2015-2019” report to their offering. The global ophthalmology d…
Glaukos Technologies Featured in Podium and Poster Presentations at 2015 American Academy of Ophthalmology
LAS VEGAS–(BUSINESS WIRE)–Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures designed to transform the treatment of glaucoma, announced today that its products will be featured in several presentations and courses at the annual American Academy of Ophthalmology (AAO) meeting being held in Las Vegas, Nevada on November 14 – 17, 2015. In addition, Glaukos will host a major symposium
International Study Shows Sustained Reduction in Intraocular Pressure through Three Years with Two Glaukos iStent® Trabecular Micro-Bypass Stents in Phakic and Pseudophakic Glaucoma Patients
LAGUNA HILLS, Calif.–(BUSINESS WIRE)–Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures designed to transform the treatment of glaucoma, today announced that a new international study, published in the November 2015 issue of Clinical Ophthalmology, showed that two iStent® Trabecular Micro-Bypass Stents provided “statistically significant, sustained and safe reduction in intraocular
Vision Medicines Announces Co-Funding Agreement for Stargardt Disease Program with Foundation Fighting Blindness
BOSTON–(BUSINESS WIRE)–Vision Medicines announces largest co-funding agreement to date with Foundation Fighting Blindness for Stargardt disease program. Stargardt is an orphan disease that leads to legal blindness.
Vision Medicines Announces Exclusive Worldwide Licensing Agreement with Case Western Reserve University for Stargardt Disease Drug Candidate
BOSTON–(BUSINESS WIRE)–Vision Medicines announces exclusive worldwide license from Case Western Reserve University for drug candidate for Stargardt disease. Stargardt leads to legal blindness.